NCT05194995 2026-03-16JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationAllist Pharmaceuticals, Inc.Phase 1/2 Active not recruiting48 enrolled
NCT04902872 2025-01-23Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsCybrexa TherapeuticsPhase 1/2 Active not recruiting130 enrolled
NCT05462717 2024-11-07Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled